Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0197)
Name
Romidepsin
Synonyms
Romidepsin; Depsipeptide; FK228; Chromadax; 128517-07-7; Istodax; Antibiotic FR 901228; FR901228; FK 228; FK-228; FR 901228; FR-901228; NSC-630176; C24H36N4O6S2; NSC 630176; CHEMBL343448; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; CHEBI:61080; NSC630176; NSC754143; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; Istodax (TN); Romidepsin [USAN]; CX3T89XQBK; HDInhib_000006; romidepsina; romidepsine; romidepsinum; OXA-12,8,20,23-TETRAZABICYCLO[8.7.6]TRICOSANE, CYCLIC PEPTIDE DERIV.; Romidepsin (FK228); Romidepsin; FK-228; ROMIDEPSIN [MI]; FK-901228; ROMIDEPSIN [INN]; ROMIDEPSIN [JAN]; ROMIDEPSIN [VANDF]; Probes1_000153; Probes2_000337; ROMIDEPSIN [MART.]; ROMIDEPSIN [WHO-DD]; DEPSIPEPTIDE [WHO-DD]; Romidepsin (JAN/USAN/INN); SCHEMBL677497; GTPL7006; ROMIDEPSIN [ORANGE BOOK]; Romidepsin, >=98% (HPLC); BDBM19151; Romidepsin (FK228 ,depsipeptide); (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (3->5)-disulfide; HB1386; MFCD18433404; s3020; API0005301; CS-0985; DB06176; NSC-754143; HY-15149; D06637; AB01273968-01; EN300-22844947; SR-01000941579; Q7363205; SR-01000941579-1; L-Valine,3-didehydro-2- aminobutanoyl-,.xi.-lactone, cyclic (1.fwdarw.2)-disulfide; L-Valine,3-didehydro-2-aminobutanoyl-,.xi.-lactone, cyclic (1.fwdarw.2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7- ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23- tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(1methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16ene-3,6,9,19,22-pentone; (E)-(1S,10S,21R)-7-[(Z)-Ethylidene]-4,21-diisopropyl-2- oxa-12,13-dithia-5,8,20,23- tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (E)-(1S,10S,21R)-7-[(Z)-Ethylidene]-4,21-diisopropyl-2- oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; CYCLO((2Z)-2-AMINO-2-BUTENOYL-L-VALYL-(3S,4E)-3-HYDROXY-7-MERCAPTO-4-HEPTENOYL-D-VALYL-D-CYSTEINYL), CYCLIC (3->5)-DISULPHIDE; Cyclo[(2Z)-2-amino-2-butenoyl-L-val yl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valy l-D-cysteinyl], cyclic (3-5) disulfide; Cyclo[(2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl], cyclic (3-5) disulfide

    Click to Show/Hide
Structure
Formula
C24H36N4O6S2
IUPAC Name
(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone
Canonical SMILES
CC=C1C(=O)NC(C(=O)OC2CC(=O)NC(C(=O)NC(CSSCCC=C2)C(=O)N1)C(C)C)C(C)C
InChI
InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20+/m1/s1
InChIKey
OHRURASPPZQGQM-GCCNXGTGSA-N
PubChem CID
5352062
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
In total 2 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Adrenocortical carcinoma ICD-11: 2D11
 Disease Info 
Responsed Regulator Histone deacetylase 1 (HDAC1) Suppressor
 Regulator Info 
Pathway Response Cell adhesion molecules hsa04514
Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model SW13 cells Adrenal cortex carcinoma Homo sapiens CVCL_0542
Response regulation HDAC inhibitor Romidepsin converted SW13+ cells also had reduced mRNA expression of the mitochondrial ROS detoxifier superoxide dismutase 2 (SOD2), and the tumor suppressor p53. HDAC inhibitor treatment synergistically increased adrenocortical carcinoma cell death following induction of ferroptosis.
Experiment 2 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Adrenocortical carcinoma ICD-11: 2D11
 Disease Info 
Responsed Regulator Cellular tumor antigen p53 (TP53) Driver
 Regulator Info 
Pathway Response Cell adhesion molecules hsa04514
Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model SW13 cells Adrenal cortex carcinoma Homo sapiens CVCL_0542
Response regulation HDAC inhibitor Romidepsin converted SW13+ cells also had reduced mRNA expression of the mitochondrial ROS detoxifier superoxide dismutase 2 (SOD2), and the tumor suppressor p53. HDAC inhibitor treatment synergistically increased adrenocortical carcinoma cell death following induction of ferroptosis.
References
Ref 1 HDAC inhibition induces EMT and alterations in cellular iron homeostasis to augment ferroptosis sensitivity in SW13 cells. Redox Biol. 2021 Nov;47:102149. doi: 10.1016/j.redox.2021.102149. Epub 2021 Sep 25.